Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$4.72 -11.1%	$4.36	$1.58 ▼ $7.27	$420.75M	-0.6	1.22 million shs	1.02 million shs
KDNY Chinook Therapeutics	$40.39	$39.86	$18.34 ▼ $40.51	$2.90B	0.34	1.19 million shs	N/A
XNCR Xencor	$7.75 +2.4%	$9.45	$7.16 ▼ $27.24	$551.58M	0.99	657,047 shs	1.49 million shs
ZNTL Zentalis Pharmaceuticals	$1.20	$1.35	$1.01 ▼ $13.00	$86.34M	1.81	1.56 million shs	558,144 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-11.11%	-14.49%	-11.94%	+47.50%	+172.83%
KDNY Chinook Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
XNCR Xencor	+2.38%	-4.79%	-26.26%	-46.11%	-67.16%
ZNTL Zentalis Pharmaceuticals	0.00%	-6.25%	-16.08%	-44.19%	-89.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.4466 of 5 stars	3.6	2.0	0.0	0.0	3.3	4.2	1.3
KDNY Chinook Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	3.9356 of 5 stars	3.4	1.0	0.0	3.9	3.7	0.8	1.3
ZNTL Zentalis Pharmaceuticals	1.7715 of 5 stars	3.2	1.0	0.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.13	Buy	$9.83	108.33% Upside
KDNY Chinook Therapeutics	0.00	N/A	N/A	N/A
XNCR Xencor	2.89	Moderate Buy	$29.50	280.65% Upside
ZNTL Zentalis Pharmaceuticals	2.44	Hold	$8.24	587.04% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, AMLX, KDNY, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/7/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $7.00
3/28/2025	ZNTL Zentalis Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-330.77	$0.86 per share	5.51	$6.42 per share	0.74
KDNY Chinook Therapeutics	$6.13M	473.15	N/A	N/A	$6.91 per share	5.85
XNCR Xencor	$127.23M	4.34	N/A	N/A	$10.99 per share	0.71
ZNTL Zentalis Pharmaceuticals	$26.87M	3.21	N/A	N/A	$6.18 per share	0.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	8/14/2025 (Estimated)
KDNY Chinook Therapeutics	-$187.87M	-$3.52	N/A	N/A	N/A	-4,199.93%	-58.28%	-44.72%	N/A
XNCR Xencor	-$126.09M	-$3.06	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	8/4/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$292.19M	-$3.13	N/A	N/A	N/A	N/A	-43.91%	-34.96%	8/8/2025 (Estimated)

Latest ZNTL, AMLX, KDNY, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
3/26/2025	Q4 2024	ZNTL Zentalis Pharmaceuticals	-$0.75	-$0.66	+$0.09	-$0.66	N/A	$26.90 million
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	21.53%	N/A	N/A	N/A
KDNY Chinook Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
KDNY Chinook Therapeutics	N/A	5.82	5.82
XNCR Xencor	0.01	6.23	6.23
ZNTL Zentalis Pharmaceuticals	N/A	7.29	7.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
KDNY Chinook Therapeutics	95.15%
XNCR Xencor	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
KDNY Chinook Therapeutics	16.79%
XNCR Xencor	4.76%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	60.53 million	Optionable
KDNY Chinook Therapeutics	214	71.81 million	59.75 million	Optionable
XNCR Xencor	280	71.17 million	66.32 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	68.70 million	Optionable

ZNTL, AMLX, KDNY, and XNCR Headlines

Recent News About These Companies

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Lessened by Woodline Partners LP

May 27 at 4:31 AM | marketbeat.com

Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $8.24

May 26 at 2:09 AM | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by Analysts

May 25 at 1:31 AM | marketbeat.com

Jacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 20, 2025 | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for ZNTL

May 20, 2025 | marketbeat.com

Wedbush Issues Optimistic Outlook for ZNTL Earnings

May 20, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Neutral Rating from Wedbush

May 18, 2025 | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLC

May 16, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

Integral Health Asset Management LLC Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 14, 2025 | marketbeat.com

Almitas Capital LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 4, 2025 | marketbeat.com

Boxer Capital Management LLC Makes New $1.36 Million Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

May 4, 2025 | marketbeat.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Tuesday

May 1, 2025 | marketbeat.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by Brokerages

April 29, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Decheng Capital LLC Trims Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

April 28, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, AMLX, KDNY, and XNCR Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.72 -0.59 (-11.11%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$4.78 +0.07 (+1.38%)

As of 05/27/2025 07:56 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Chinook Therapeutics NASDAQ:KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

Xencor NASDAQ:XNCR

$7.75 +0.18 (+2.38%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.76 +0.00 (+0.06%)

As of 05/27/2025 04:28 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.20 0.00 (0.00%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.50%)

As of 05/27/2025 06:23 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time